Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Verve Therapeutics Inc Logo

ARKG Holdings of Verve Therapeutics (VERV) - Updated Daily

Gene TherapyGenomicsCRSPR Gene Editing
Maxinomics.com icon
YouTube Logo
Date
Direction
Shares
Fund Weight
Fund
January 13, 2023
BUY5.444k0.0055%ARKG
January 11, 2023
BUY9.857k0.0101%ARKG
January 6, 2023
BUY1.338k0.0014%ARKG
January 3, 2023
BUY91.148k0.0907%ARKG
December 22, 2022
BUY484.0000.0004%ARKG

Key Statistics

🕵🏼Found In🏷Last Price
ARKGARKK$24.01
⚖️Weighting🧢Market Cap
2.74%$1.48b
🏋🏿‍♂️Weight Rank In ARKG🧮Price to Sales
151592.15
🏋️‍♀️Weight Rank Across All Funds🌏Country
28🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$37.814.55%
Description
Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.
Website
www.vervetx.com

Research Notes and Commentary for VERV

No Research Notes Found for VERV